Search research articles
Contact Us
Filters
Showing results (41-50 of 74) with videos related to
Page
of 8
Sort By:
European Urology Oncology
|
April 4, 2024
Papillary Renal Cell Carcinoma: Outcomes for Patients Receiving First-line Immune-based Combinations or Tyrosine Kinase Inhibitors from the ARON-1 Study
Francesco Massari, Veronica Mollica, Ondrej Fiala, et al.
European Urology Oncology
|
February 26, 2023
A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma
Bradley McGregor, Daniel M Geynisman, Mauricio Burotto, et al.
Cancer Medicine
|
February 21, 2025
Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective Experience
Mimma Rizzo, Franco Morelli, Yüksel Ürün, et al.
Targeted Oncology
|
August 6, 2024
Pembrolizumab in Patients with Advanced Urothelial Carcinoma with ECOG Performance Status 2: A Real-World Study from the ARON-2 Project
Alessandro Rizzo, Fernando Sabino Marques Monteiro, Yüksel Ürün, et al.
Frontiers in Oncology
|
December 4, 2023
Impact of healthcare inequities on survival in Mexican patients with metastatic renal cell carcinoma
Maria T Bourlon, Yuly A Remolina-Bonilla, Aldo A Acosta-Medina, et al.
International Journal of Cancer
|
November 4, 2025
Toxicity-related immunotherapy discontinuation and outcome in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1 study)
Javier Molina-Cerrillo, Giandomenico Roviello, Maria T Bourlon, et al.
Frontiers in Immunology
|
May 6, 2026
Real-world incidence of G3-G4 adverse events in patients with advanced renal cell carcinoma receiving immune-combinations (ARON-1)
Evelyn L Beas-Lozano, Sarah Scagliarini, Paola I Valdez-Sandoval, et al.
Journal of Global Oncology
|
April 8, 2020
Barriers and Opportunities of Oncofertility Practice in Nine Developing Countries and the Emerging Oncofertility Professional Engagement Network
Mahmoud Salama, Lauren Ataman-Millhouse, Fabio Sobral, et al.
Prostate Cancer and Prostatic Diseases
|
January 7, 2026
Enzalutamide in metastatic hormone-sensitive prostate cancer: results from the international, multicentre, real-world ARON-3 study
Thomas Büttner, Mimma Rizzo, Laura Bernal Vaca, et al.
JCO Global Oncology
|
March 11, 2022
Barriers and Opportunities of Oncofertility Practice in Nine Developing Countries and the Emerging Oncofertility Professional Engagement Network
Mahmoud Salama, Lauren Ataman-Millhouse, Fabio Sobral, et al.
Page
of 8
Search research articles
Search
Showing results (41-50 of 74) with videos related to
Sort By:
Page
of 8
European Urology Oncology
|
April 4, 2024
Papillary Renal Cell Carcinoma: Outcomes for Patients Receiving First-line Immune-based Combinations or Tyrosine Kinase Inhibitors from the ARON-1 Study
Francesco Massari, Veronica Mollica, Ondrej Fiala, et al.
European Urology Oncology
|
February 26, 2023
A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma
Bradley McGregor, Daniel M Geynisman, Mauricio Burotto, et al.
Cancer Medicine
|
February 21, 2025
Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective Experience
Mimma Rizzo, Franco Morelli, Yüksel Ürün, et al.
Targeted Oncology
|
August 6, 2024
Pembrolizumab in Patients with Advanced Urothelial Carcinoma with ECOG Performance Status 2: A Real-World Study from the ARON-2 Project
Alessandro Rizzo, Fernando Sabino Marques Monteiro, Yüksel Ürün, et al.
Frontiers in Oncology
|
December 4, 2023
Impact of healthcare inequities on survival in Mexican patients with metastatic renal cell carcinoma
Maria T Bourlon, Yuly A Remolina-Bonilla, Aldo A Acosta-Medina, et al.
International Journal of Cancer
|
November 4, 2025
Toxicity-related immunotherapy discontinuation and outcome in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1 study)
Javier Molina-Cerrillo, Giandomenico Roviello, Maria T Bourlon, et al.
Frontiers in Immunology
|
May 6, 2026
Real-world incidence of G3-G4 adverse events in patients with advanced renal cell carcinoma receiving immune-combinations (ARON-1)
Evelyn L Beas-Lozano, Sarah Scagliarini, Paola I Valdez-Sandoval, et al.
Journal of Global Oncology
|
April 8, 2020
Barriers and Opportunities of Oncofertility Practice in Nine Developing Countries and the Emerging Oncofertility Professional Engagement Network
Mahmoud Salama, Lauren Ataman-Millhouse, Fabio Sobral, et al.
Prostate Cancer and Prostatic Diseases
|
January 7, 2026
Enzalutamide in metastatic hormone-sensitive prostate cancer: results from the international, multicentre, real-world ARON-3 study
Thomas Büttner, Mimma Rizzo, Laura Bernal Vaca, et al.
JCO Global Oncology
|
March 11, 2022
Barriers and Opportunities of Oncofertility Practice in Nine Developing Countries and the Emerging Oncofertility Professional Engagement Network
Mahmoud Salama, Lauren Ataman-Millhouse, Fabio Sobral, et al.
Page
of 8